{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:18Z","timestamp":1792784898195,"version":"4.5.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":115,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA","id":[{"id":"https:\/\/ror.org\/02891sr49","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pembrolizumab plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in the phase 3 randomized KEYNOTE-355 study in participants with previously untreated, advanced triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS)\u2009\u2265\u200910. Among participants with clinical benefit from pembrolizumab plus chemotherapy, discontinuation of chemotherapy before pembrolizumab for any reason was associated with similar median PFS and OS to that in the overall population. Additionally, we further characterized immune-mediated adverse events (AEs) in KEYNOTE-355. Most immune-mediated AEs were manageable with treatment interruption and supportive care. In participants treated with pembrolizumab plus chemotherapy with immune-mediated AEs, there appeared to be numerical improvement in efficacy. This analysis provides additional information on the use of pembrolizumab plus chemotherapy as standard-of-care therapy in patients with previously untreated, advanced TNBC with PD-L1 CPS\u2009\u2265\u200910. This trial is registered at ClinicalTrials.gov (NCT02819518; registration date, June 28, 2016).<\/jats:p>","DOI":"10.1038\/s41523-026-00971-8","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:16:37Z","timestamp":1782508597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events"],"prefix":"10.1038","volume":"12","author":[{"given":"Hope S.","family":"Rugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Cescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Nowecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Md Yusof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Lipatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Henrique","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Hegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Torregroza","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"\u00c1rkosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Tarnawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Mejia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbur","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"971_CR1","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"971_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med, 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med"},{"key":"971_CR3","unstructured":"Keytruda (pembrolizumab). Full Prescribing Information, Merck Sharp & Dohme LLC, Rahway, NJ, USA, 2025."},{"key":"971_CR4","unstructured":"Keytruda (pembrolizumab). Summary of Product Characteristics, Merck Sharp & Dohme B.V., Haarlem, The Netherlands, 2025."},{"key":"971_CR5","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda, R. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460\u20132467 (2016).","journal-title":"J. Clin. Oncol."},{"key":"971_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer, E. P. et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 499\u2013511 (2021).","journal-title":"Lancet Oncol."},{"key":"971_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113530","volume":"199","author":"JR Brahmer","year":"2024","unstructured":"Brahmer, J. R. et al. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur. J. Cancer 199, 113530 (2024).","journal-title":"Eur. J. Cancer"},{"key":"971_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","volume":"109","author":"J Rogado","year":"2019","unstructured":"Rogado, J. et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur. J. Cancer 109, 21\u201327 (2019).","journal-title":"Eur. J. Cancer"},{"key":"971_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/jjco\/hyae067","volume":"54","author":"T Fukushima","year":"2024","unstructured":"Fukushima, T., Kobayashi, S. & Ueno, M. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors. Jpn J. Clin. Oncol. 54, 949\u2013958 (2024).","journal-title":"Jpn J. Clin. Oncol."},{"key":"971_CR10","doi-asserted-by":"publisher","first-page":"1190001","DOI":"10.3389\/fphar.2023.1190001","volume":"14","author":"L Lin","year":"2023","unstructured":"Lin, L., Liu, Y., Chen, C., Wei, A. & Li, W. Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis. Front. Pharm. 14, 1190001 (2023).","journal-title":"Front. Pharm."},{"key":"971_CR11","doi-asserted-by":"publisher","first-page":"e003965","DOI":"10.1136\/jitc-2021-003965","volume":"10","author":"T Kawai","year":"2022","unstructured":"Kawai, T. et al. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis. J. Immunother. Cancer 10, e003965 (2022).","journal-title":"J. Immunother. Cancer"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00971-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00971-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00971-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:09:01Z","timestamp":1792364941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00971-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["971"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00971-8","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hope S. Rugo: Consultancy\/advisory support: Napo, Bristol Myers Squibb, Helsinn, and BioNTech; institutional research funding to her prior institution (UCSF) from AstraZeneca, Gilead Sciences, Inc., Lilly, Merck & Co., Daiichi Sankyo, Inc., Novartis Pharmaceuticals, Pfizer, F. Hoffman-La Roche\/Genentech, Stemline Therapeutics, and Ambryx; institutional research funding to City of Hope from Bicycle Therapeutics, F. Hoffman-La Roche\/Genentech, PhoenixMD, Merck, Relay Therapeutics, ALX Oncology, Pfizer, Mabwell and Stemline Therapeutics. David Cescon: Consultancy and advisory relationship: AstraZeneca, Daiichi Sankyo, Exact Sciences, GenomeRx, Gilead, Glaxo SmithKline, Inivata\/NeoGenomics, Lilly, Merck, Novartis, Pfizer, Roche, and SAGA; research funding to institution: AstraZeneca, GenomeRx, Guardant Health, Grail, Gilead, Glaxo SmithKline, Inivata\/NeoGenomics, Knight, Merck, Pfizer, ProteinQure, RayzeBio and Roche. Peter Schmid: Consultant to or received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Puma, Roche, Eisai, and Celgene; grant\/funding (to institution) from Astellas, AstraZeneca, Genentech, Novartis, Oncogenex, Roche, Medivation, and Merck. Zbigniew Nowecki: None declared. Seock-Ah Im: Advisory role for AstraZeneca, Daiichi-Sankyo, GSK, Hanmi, Idience, Lilly, MSD, Novartis, Pfizer, Bertis, and Roche; and grants for AstraZeneca, Boryung Pharm, Daewoong Pharm, Daiichi-Sankyo, Eisai, Pfizer, and Roche. Mastura Md Yusof: Honoraria from Amgen, AstraZeneca, Gilead, Menarini, MSD, Zuellig Pharma, Pfizer, Roche; grant funding (to institution) from Amgen, Menarini, AstraZeneca, MSD, Novartis, Gilead, Celcuity; consulting for DKSH, Novartis, AstraZeneca, Zuellig Pharma, MSD, Pfizer, Gilead, Roche, Menarini, Amgen; and support for attending meetings and\/or travel from AstraZeneca, MSD, Zuellig Pharma, Juniper Biologics. Carlos Gallardo: Consulting or advisory role - Lilly; MSD; Roche; speakers bureau - Bristol-Myers Squibb; research funding - Novartis Pharma SAS; Roche; travel, accommodations, expenses - MSD; Roche. Hiroji Iwata: Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Gilead; Lilly Japan; MSD; Myriad Genetics; Pfizer; consulting or advisory role - AstraZeneca; Chugai Pharma; CMIC; Daiichi Sankyo; Gilead; Lilly Japan; Novartis; MSD; Pfizer; research funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo; MSD; Novartis (all to institution). Oleg Lipatov: None declared. Felipe Cruz: None declared. Carlos H. Barrios: Grants\/research support (to institution): Amgen, Astra Zeneca, Aveo Oncology, BioNTech, BMS, Daiichi Sankyo, Dizal Pharma, Exelixis, Fortrea, Gilead Sciences, GSK, ICON, IQVIA, Janssen, Labcorp, Lilly, Medpace, MSD, Novartis, Novocure, Nuvisan, OBI Pharma, Parexel, Pfizer, PharmaMar, PPD, PSI, Regeneron, Roche\/Genentech, Samsung, Sandoz, Sanofi, Seagen, Servier, Stemline, Syneos Health, Taiho, Takeda, Tolmar, TRIO, Worldwide; advisory boards, consulting, travel, presentation honoraria: Adium, Novartis, Pfizer, Roche\/Genentech, MSD, Astra Zeneca, Lilly, Daiichi, Gilead; and stock or stock options: MEDSir, CPO, Tummi. Roberto Hegg: None declared. Sherene Loi: Research funding to her institution from Novartis, Bristol-Myers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca, and Seattle Genetics; she has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, Eli Lilly, Pfizer, Gilead Therapeutics, and Roche-Genentech; she has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, Glaxo SmithKline, Roche-Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics, Daiichi Sankyo, Merck, Amunix, Tallac Therapeutics, Eli Lilly, and Bristol-Myers Squibb. Maria Gion: Honoraria: Novartis, Gilead, AstraZeneca, and Pfizer; travel grants, accommodation: Roche, Pfizer, AstraZeneca, and Gilead; advisory role: MEDSIR, Gilead, Novartis, AstraZeneca, and Pfizer. Marco Torregroza Otero: None declared. P\u00e9ter \u00c1rkosy: None declared. Rafal Tarnawski: Glaxo SmithKline, AstraZeneca, and MSD. Lili Yao, Jaime Mejia, and Wilbur Pan: Employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and owns stock in Merck & Co., Inc., Rahway, NJ, USA. Javier Cort\u00e9s: Consulting\/advisor: Roche, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, MSD, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, AbbVie, BridgeBio, Biontech, Biocon, Circle Pharma, Delcath Systems, Inc., Hexagon Bio, Bliss Biopharmaceutical; honoraria: Roche, Novartis, Eisai, Pfizer, Lilly, MSD, Daiichi Sankyo, AstraZeneca, Gilead, Steamline Therapeutics, Zuellig Pharma; research funding to institution: Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH\/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardant Health, MSD, Pfizer, Piqur Therapeutics, Iqvia, Queen Mary University of London; stock MAJ3 Capital, Leuko (relative); travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, AstraZeneca, Gilead, MSD, Steamline Therapeutics; patents: Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cort\u00e9s Cast\u00e1n, Alejandro Piris Gim\u00e9nez, Violeta Serra Elizalde. WO 2014\/199294 A. ISSUED; Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cort\u00e9s. US 2019\/ 0338368 A1. LICENSED.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"137"}}